Pracinostat has been shown to be an effective therapy for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) in several Phase I and Phase II studies. Here, Guillermo Garcia-Manero, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, speaks about a new, worldwide Phase III trial (NCT03151408) which is currently underway to explore whether the addition of pracinostat to azacitidine therapy increases the efficacy of treatment in AML patients over 75 years old, or those who are not candidates for intensive chemotherapy. This interview took place at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
addition of pracinostat to azacitidine, acute myeloid leukemia (aml), aml, asco 2018, american society of oncology (asco), myelodysplastic syndromes (mds), mds